Masimo Corporation (NASDAQ:MASI) had its price target raised by research analysts at Roth Capital from $96.00 to $105.00 in a note issued to investors on Wednesday. The firm currently has a “buy” rating on the medical equipment provider’s stock. Roth Capital’s price target indicates a potential upside of 10.36% from the stock’s previous close.

Other equities research analysts also recently issued reports about the stock. Wedbush reiterated an “outperform” rating and set a $100.00 price target on shares of Masimo Corporation in a report on Tuesday, April 4th. BidaskClub upgraded shares of Masimo Corporation from a “hold” rating to a “buy” rating in a report on Wednesday, July 12th. Stifel Nicolaus began coverage on shares of Masimo Corporation in a report on Monday, July 10th. They set a “buy” rating and a $105.00 price target for the company. Finally, Zacks Investment Research downgraded shares of Masimo Corporation from a “hold” rating to a “sell” rating in a report on Tuesday, July 4th. Five investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $87.00.

Shares of Masimo Corporation (MASI) opened at 95.14 on Wednesday. The firm has a 50-day moving average price of $91.54 and a 200-day moving average price of $87.54. The stock has a market cap of $4.87 billion, a price-to-earnings ratio of 16.16 and a beta of 0.80. Masimo Corporation has a 52 week low of $51.10 and a 52 week high of $104.71.

Masimo Corporation (NASDAQ:MASI) last posted its earnings results on Wednesday, May 3rd. The medical equipment provider reported $0.82 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.60 by $0.22. The firm had revenue of $186.30 million during the quarter, compared to the consensus estimate of $184.14 million. Masimo Corporation had a net margin of 44.86% and a return on equity of 24.19%. The firm’s revenue for the quarter was up 8.8% on a year-over-year basis. During the same period last year, the firm posted $0.53 EPS. On average, equities analysts anticipate that Masimo Corporation will post $2.66 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Masimo Corporation (MASI) Price Target Increased to $105.00 by Analysts at Roth Capital” was first published by American Banking News and is the property of of American Banking News. If you are accessing this story on another site, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/07/19/masimo-corporation-masi-price-target-increased-to-105-00-by-analysts-at-roth-capital.html.

In other news, Director Sanford Fitch sold 6,000 shares of the business’s stock in a transaction on Thursday, July 13th. The shares were sold at an average price of $91.89, for a total transaction of $551,340.00. Following the transaction, the director now directly owns 89,249 shares of the company’s stock, valued at $8,201,090.61. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Rick Fishel sold 15,000 shares of the business’s stock in a transaction on Friday, July 14th. The stock was sold at an average price of $94.85, for a total transaction of $1,422,750.00. Following the transaction, the insider now directly owns 35,022 shares in the company, valued at $3,321,836.70. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 591,201 shares of company stock valued at $58,635,376. 16.60% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Capstone Asset Management Company boosted its position in Masimo Corporation by 14.7% in the fourth quarter. Capstone Asset Management Company now owns 16,946 shares of the medical equipment provider’s stock worth $703,000 after buying an additional 2,170 shares during the last quarter. Acadian Asset Management boosted its position in Masimo Corporation by 6,598.8% in the fourth quarter. Acadian Asset Management now owns 16,814 shares of the medical equipment provider’s stock worth $699,000 after buying an additional 16,563 shares during the last quarter. Isthmus Partners LLC boosted its position in Masimo Corporation by 3.6% in the fourth quarter. Isthmus Partners LLC now owns 19,993 shares of the medical equipment provider’s stock worth $830,000 after buying an additional 698 shares during the last quarter. Eagle Asset Management boosted its position in Masimo Corporation by 83.4% in the third quarter. Eagle Asset Management now owns 138,170 shares of the medical equipment provider’s stock worth $5,326,000 after buying an additional 62,814 shares during the last quarter. Finally, Hanseatic Management Services Inc. boosted its position in Masimo Corporation by 10.4% in the fourth quarter. Hanseatic Management Services Inc. now owns 21,927 shares of the medical equipment provider’s stock worth $910,000 after buying an additional 2,060 shares during the last quarter. 83.59% of the stock is currently owned by institutional investors and hedge funds.

Masimo Corporation Company Profile

Masimo Corporation is a medical technology company that develops, manufactures and markets a range of non-invasive patient monitoring technologies. The Company’s business is Measure-through Motion and Low Perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry.

Analyst Recommendations for Masimo Corporation (NASDAQ:MASI)

Receive News & Ratings for Masimo Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo Corporation and related companies with MarketBeat.com's FREE daily email newsletter.